CancerNCT01676012
Hd-bronchoscopy, Comparison to Standard White Light and Autofluorescence Bronchoscopy
An observational study of Cancer, run by Radboud University Medical Center at 1 site in Netherlands.
Trial summary
Through technological improvement a new technique has become available in the form of high-definition (HD-) bronchoscopy. Current normal video white light bronchoscopy is the standard, and video-autofluorescence bronchoscopy (AFB) is offered by specialized centers only. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- How many people
- 32 participants
- Where
- 1 siteNetherlands
- Study dates
- Sep 2012to Mar 2014
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with suspected or proven head and neck or lung cancer fit for surgery and scheduled for diagnostic or therapeutic surgical procedure in the Radboud University Medical Center Nijmegen
Who may be able to join
- Patients fit for surgery and scheduled for diagnostic or therapeutic surgical procedure under general anesthesia by the cardiothoracic or thoracic surgeon or ENT surgeon with suspected or proven lung cancer or head and neck cancer.
- ASA physical status 1-3.
- Age 18 years or older.
- informed consent
Who cannot join
- Contraindications are all known contraindications for diagnostic bronchoscopy such as:
- bleeding disorders,
- indication for use of anticoagulant therapy (acenocoumarol, warfarins, therapeutic dose of low molecular weight heparins or clopidogrel),
- known allergy for lidocaine,
- known pulmonary hypertension,
- recent and/or uncontrolled cardiac disease. Presence of contraindications for the use of laryngeal mask (anatomical abnormalities) increased risk for intubation (mallampati score 4), or compromised upper airway due to extension of primary head and neck cancer.
- ASA classification greater than or equal to 4.
Trial locations and contacts
1 site in 1 country.
Netherlands1 site
Radboud University Medical Center Nijmegen
Nijmegen, Geert Grooteplein 10, 6525 GA
About this study
Official title: High Definition Bronchoscopy; an Exploratory Study of Diagnostic Value in Comparison to Standard White Light Bronchoscopy and Autofluorescence Bronchoscopy
Through technological improvement a new technique has become available in the form of high-definition (HD-) bronchoscopy. Current normal video white light bronchoscopy is the standard, and video-autofluorescence bronchoscopy (AFB) is offered by specialized centers only. The impact of this development with high-definition videobronchoscopy using a 1.1 megapixel chip on the diagnostic performance of bronchoscopy is however unknown.
The aim of the present study therefore is to explore the diagnostic performance (sensitivity and specificity) of HD-videobronchoscopy, HD + surface enhancement (iScan filtering technique) and HD + tone enhancement filtering in comparison to standard WLB and dual mode SAFE3000 autofluorescence videobronchoscopy in a high risk population.
Read the detailed description
Rationale Bronchoscopy is one of the most important procedures in diagnosis of lung cancer and other pulmonary diseases. This procedures renders important anatomical information and subtle changes in the epithelium or vascularity of the bronchial tree are clues to guide the endoscopist in this procedure, especially in case of centrally located lung cancer. These subtle changes may influence the choice of treatment, site of biopsy and resectability of cancers when determining resection margins but also in case of multifocal premalignant disease. A recently published meta-analysis has shown diagnostic superiority of autofluorescence bronchoscopy (AFB) over routine white light bronchoscopy (WLB). Furthermore, patients with a head and neck cancer have an increased risk of developing lung cancer given their smoking habits. Through technological improvement a new technique has become available in the form of high-definition (HD-) bronchoscopy. Current normal video white light bronchoscopy is the standard, and video-autofluorescence bronchoscopy (AFB) is offered by specialized centers only. The impact of this development with high-definition videobronchoscopy using a 1.1 megapixel chip on the diagnostic performance of bronchoscopy is however unknown.
Objective (primary and secondary outcome)
(1) Investigate sensitivity of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to AFB (the 'gold standard') and standard WLB for detecting abnormalities of the tracheobronchial tree. Furthermore we aim to investigate determination of resection margins of (suspected) malignancies in the glottic and supraglottic area or centrally located lung cancer in comparison to autofluorescence bronchoscopy (SAFE 3000 dual video mode) in a high risk population with biopsies from all suspect lesions identified by either technique. (2) When the sensitivity and specificity of HD videobronchoscopy in either mode in the abovementioned study is in the vicinity of the reported sensitivity and specificity of SAFE3000 dual mode videobronchoscopy we suggest to use the results of this study perform a power analysis. With this information it may then be possible to design a new future study to compare sensitivity for detecting premalignant lesions in a high risk population in a prospective study.
Study design This study is a descriptive exploratory randomized observational study with a blinded post procedure analysis of the diagnostic performance of HD bronchoscopy in comparison to WLB and AFB.
Study population Patients scheduled for diagnostic or therapeutic procedure under general anesthesia by the cardiothoracic or thoracic surgeon or ear-, nose- and throat (ENT) surgeon with suspected or proven lung cancer or head and neck cancer are eligible for this exploratory study. Eligible are patients with ASA physical status 1-3 patients aged 18 years or older. Ineligibility criteria are all known contraindications for diagnostic bronchoscopy (bleeding disorders, indication for use of anticoagulant therapy (acenocoumarol, warfarins, therapeutic dose of low molecular weight heparins or clopidogrel), known allergy for lidocaine, known pulmonary hypertension, recent and/or uncontrolled cardiac disease). Presence of contraindications for the use of laryngeal mask (anatomical abnormalities, increased risk for intubation (mallampati score 4), ASA classification greater than or equal to 4.
Study procedure Prior to surgery by the ENT surgeon or cardiothoracic surgeon bronchoscopy will be performed by an experienced chest physician through a laryngeal mask under general anaesthesia. Bronchoscopy will be performed in a standardized order using five different imaging modes. The order of the different modes will be randomized. High-definition digital videos will be made from all procedures without in screen indications of date, time or reference to study site or patient identification. The five imaging modes used in this study are: Standard white light videobronchoscopy (WLB); High Definition (HD-) bronchoscopy; HD-bronchoscopy + surface enhancement; HD-bronchoscopy + tone enhancement and Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode. All visible abnormalities suspected for malignancy or pre-malignancy will be biopsied afterwards. The HD-digital video's will be reviewed by the experienced bronchoscopists in random order and blinded for patient, study site and date and scored using a predefined scoring system to describe surface, vascularity and tumours. Premalignant lesions identified by multiple techniques are considered as non-inferior. From each patient 5 HD- films will be generated. These films will be reviewed in a blinded fashion and random order by two experienced pulmonologists and an independent equally experienced third pulmonologist. When new clinically relevant abnormalities are found the normally indicated diagnostic procedures will be followed and performed immediately after completion of the videoregistration. All findings will be disclosed to the patient and the physician in charge by the investigator and the impact of these findings on the planned diagnostic or therapeutic procedure will be registered.
Main study parameter / endpoints The bronchoscopy videos will be scored by blinded experienced endoscopists on epithelial changes, vascularity changes, presence or suspicion of dysplasia, presence of suspicion of carcinoma in situ, and tumor margins. The study is a descriptive exploratory study of diagnostic performance of HD-bronchoscopy using different imaging techniques in comparison to standard white light bronchoscopy and autofluorescence bronchoscopy in determining epithelial changes, changes in vascularity and tumour margins. As a secondary outcome we aim, when differences are established between the different bronchoscopy modes, to perform a power analysis to determine the feasibility of a prospectively designed study to investigate the diagnostic performance of HD bronchoscopy.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness After start of the general anaesthesia for the planned operation a laryngeal mask airway is inserted by the anesthesiologist. Bronchoscopy is then performed by a very experienced pulmonologist using routine topical anesthesics. In this way the burden for the patient and the risk of complications is very low. These patients have an indication for the planned surgical procedure and have been evaluated by an anesthesiologist prior to the procedure and are considered fit for surgery. The total anesthesia time for the planned procedure will be increased by 10 to 15 minutes.
Bronchoscopy is a very safe diagnostic procedure, the reported complications are in general attributable to te more invasive diagnostic procedures performed during that diagnostic bronchoscopy like biopsy, lavage and needle aspirations. This is not the aim of this study, invasive diagnostic procedures will only be performed in case of a clinically relevant new finding. In general we expect that the vast majority of the patients involved will not have any benefit of participating in this study
- Conditions
- Cancer
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| five types of bronchoscopy | Bronchoscopy will be performed in a standardized order using five different imaging modes. 1. Standard white light videobronchoscopy (WLB) 2. High Definition -Bronchoscopy 3. HD-bronchoscopy + surface enhancement (iScan-surface) 4. HD-bronchoscopy + tone enhancement (iScan-tone) 5. Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity
Investigate sensitivity of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to AFB (the 'gold standard') and standard WLB for detecting abnormalities of the tracheobronchial tree. So we used 5 types of bronchoscopy; SWL (=standard white light), HD (=high defenition bronchoscopy without surface/tone enhancement), HD-i-Scan1 (=high defention bronchoscopy with surface enhancement), HD-i-scan 2 (=high defenition bronchoscopy with tone enhancement), AFB (=autofluorescence bronchoscopy). Furthermore we aim to investigate determination of resection margins of (suspected) malignancies in the glottic and supraglottic area or centrally located lung cancer in comparison to autofluorescence bronchoscopy (SAFE 3000 dual video mode) in a high risk population with biopsies from all suspect lesions identified by either technique.
Measured: one year
Secondary outcomes (1)
Sensitivity and Specificity of HD Videobronchoscopy
When the sensitivity and specificity of HD videobronchoscopy in either mode in the abovementioned study is in the vicinity of the reported sensitivity and specificity of SAFE3000 dual mode videobronchoscopy we suggest to use the results of this study perform a power analysis. With this information it may then be possible to design a new future study to compare sensitivity for detecting premalignant lesions in a high risk population in a prospective study.
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2012 (estimated)
- Study startSep 2012
- Primary completionMar 2014
- Study completionMar 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Radboud University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radboud University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- HFM vanderHeijden, MD, Principal investigator, Principal Investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01676012
- Sponsor's protocol ID
- 38719
- Status last verified
- May 2015
- First submitted
- 15 Aug 2012
- Last updated
- 12 May 2015
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- High Definition Bronchoscopy; an Exploratory Study of Diagnostic Value in Comparison to Standard White Light Bronchoscopy and Autofluorescence Bronchoscopy
- ClinicalTrials.gov ID
- NCT01676012
- Acronym / sponsor ID
- 38719
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Radboud University Medical CenterUniversity, hospital or other
- Study start
- Sep 2012
- Primary completion
- Mar 2014 (actual)
- Study completion
- Mar 2014 (actual)
- First posted
- 30 Aug 2012 (estimated)
- Results
- Posted 12 May 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Through technological improvement a new technique has become available in the form of high-definition (HD-) bronchoscopy. Current normal video white light bronchoscopy is the standard, and video-autofluorescence bronchoscopy (AFB) is offered by specialized centers only. The impact of this development with high-definition videobronchoscopy using a 1.1 megapixel chip on the diagnostic performance of bronchoscopy is however unknown.
The aim of the present study therefore is to explore the diagnostic performance (sensitivity and specificity) of HD-videobronchoscopy, HD + surface enhancement (iScan filtering technique) and HD + tone enhancement filtering in comparison to standard WLB and dual mode SAFE3000 autofluorescence videobronchoscopy in a high risk population.
Detailed description
Rationale Bronchoscopy is one of the most important procedures in diagnosis of lung cancer and other pulmonary diseases. This procedures renders important anatomical information and subtle changes in the epithelium or vascularity of the bronchial tree are clues to guide the endoscopist in this procedure, especially in case of centrally located lung cancer. These subtle changes may influence the choice of treatment, site of biopsy and resectability of cancers when determining resection margins but also in case of multifocal premalignant disease. A recently published meta-analysis has shown diagnostic superiority of autofluorescence bronchoscopy (AFB) over routine white light bronchoscopy (WLB). Furthermore, patients with a head and neck cancer have an increased risk of developing lung cancer given their smoking habits. Through technological improvement a new technique has become available in the form of high-definition (HD-) bronchoscopy. Current normal video white light bronchoscopy is the standard, and video-autofluorescence bronchoscopy (AFB) is offered by specialized centers only. The impact of this development with high-definition videobronchoscopy using a 1.1 megapixel chip on the diagnostic performance of bronchoscopy is however unknown.
Objective (primary and secondary outcome)
(1) Investigate sensitivity of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to AFB (the 'gold standard') and standard WLB for detecting abnormalities of the tracheobronchial tree. Furthermore we aim to investigate determination of resection margins of (suspected) malignancies in the glottic and supraglottic area or centrally located lung cancer in comparison to autofluorescence bronchoscopy (SAFE 3000 dual video mode) in a high risk population with biopsies from all suspect lesions identified by either technique. (2) When the sensitivity and specificity of HD videobronchoscopy in either mode in the abovementioned study is in the vicinity of the reported sensitivity and specificity of SAFE3000 dual mode videobronchoscopy we suggest to use the results of this study perform a power analysis. With this information it may then be possible to design a new future study to compare sensitivity for detecting premalignant lesions in a high risk population in a prospective study.
Study design This study is a descriptive exploratory randomized observational study with a blinded post procedure analysis of the diagnostic performance of HD bronchoscopy in comparison to WLB and AFB.
Study population Patients scheduled for diagnostic or therapeutic procedure under general anesthesia by the cardiothoracic or thoracic surgeon or ear-, nose- and throat (ENT) surgeon with suspected or proven lung cancer or head and neck cancer are eligible for this exploratory study. Eligible are patients with ASA physical status 1-3 patients aged 18 years or older. Ineligibility criteria are all known contraindications for diagnostic bronchoscopy (bleeding disorders, indication for use of anticoagulant therapy (acenocoumarol, warfarins, therapeutic dose of low molecular weight heparins or clopidogrel), known allergy for lidocaine, known pulmonary hypertension, recent and/or uncontrolled cardiac disease). Presence of contraindications for the use of laryngeal mask (anatomical abnormalities, increased risk for intubation (mallampati score 4), ASA classification greater than or equal to 4.
Study procedure Prior to surgery by the ENT surgeon or cardiothoracic surgeon bronchoscopy will be performed by an experienced chest physician through a laryngeal mask under general anaesthesia. Bronchoscopy will be performed in a standardized order using five different imaging modes. The order of the different modes will be randomized. High-definition digital videos will be made from all procedures without in screen indications of date, time or reference to study site or patient identification. The five imaging modes used in this study are: Standard white light videobronchoscopy (WLB); High Definition (HD-) bronchoscopy; HD-bronchoscopy + surface enhancement; HD-bronchoscopy + tone enhancement and Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode. All visible abnormalities suspected for malignancy or pre-malignancy will be biopsied afterwards. The HD-digital video's will be reviewed by the experienced bronchoscopists in random order and blinded for patient, study site and date and scored using a predefined scoring system to describe surface, vascularity and tumours. Premalignant lesions identified by multiple techniques are considered as non-inferior. From each patient 5 HD- films will be generated. These films will be reviewed in a blinded fashion and random order by two experienced pulmonologists and an independent equally experienced third pulmonologist. When new clinically relevant abnormalities are found the normally indicated diagnostic procedures will be followed and performed immediately after completion of the videoregistration. All findings will be disclosed to the patient and the physician in charge by the investigator and the impact of these findings on the planned diagnostic or therapeutic procedure will be registered.
Main study parameter / endpoints The bronchoscopy videos will be scored by blinded experienced endoscopists on epithelial changes, vascularity changes, presence or suspicion of dysplasia, presence of suspicion of carcinoma in situ, and tumor margins. The study is a descriptive exploratory study of diagnostic performance of HD-bronchoscopy using different imaging techniques in comparison to standard white light bronchoscopy and autofluorescence bronchoscopy in determining epithelial changes, changes in vascularity and tumour margins. As a secondary outcome we aim, when differences are established between the different bronchoscopy modes, to perform a power analysis to determine the feasibility of a prospectively designed study to investigate the diagnostic performance of HD bronchoscopy.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness After start of the general anaesthesia for the planned operation a laryngeal mask airway is inserted by the anesthesiologist. Bronchoscopy is then performed by a very experienced pulmonologist using routine topical anesthesics. In this way the burden for the patient and the risk of complications is very low. These patients have an indication for the planned surgical procedure and have been evaluated by an anesthesiologist prior to the procedure and are considered fit for surgery. The total anesthesia time for the planned procedure will be increased by 10 to 15 minutes.
Bronchoscopy is a very safe diagnostic procedure, the reported complications are in general attributable to te more invasive diagnostic procedures performed during that diagnostic bronchoscopy like biopsy, lavage and needle aspirations. This is not the aim of this study, invasive diagnostic procedures will only be performed in case of a clinically relevant new finding. In general we expect that the vast majority of the patients involved will not have any benefit of participating in this study
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| five types of bronchoscopy | – | –Bronchoscopy will be performed in a standardized order using five different imaging modes. 1. Standard white light videobronchoscopy (WLB) 2. High Definition -Bronchoscopy 3. HD-bronchoscopy + surface enhancement (iScan-surface) 4. HD-bronchoscopy + tone enhancement (iScan-tone) 5. Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with suspected or proven head and neck or lung cancer fit for surgery and scheduled for diagnostic or therapeutic surgical procedure in the Radboud University Medical Center Nijmegen
Key inclusion criteria (4 listed)
- Patients fit for surgery and scheduled for diagnostic or therapeutic surgical procedure under general anesthesia by the cardiothoracic or thoracic surgeon or ENT surgeon with suspected or proven lung cancer or head and neck cancer.
- ASA physical status 1-3.
- Age 18 years or older.
- informed consent
Key exclusion criteria (7 listed)
- bleeding disorders,
- indication for use of anticoagulant therapy (acenocoumarol, warfarins, therapeutic dose of low molecular weight heparins or clopidogrel),
- known allergy for lidocaine,
- known pulmonary hypertension,
- recent and/or uncontrolled cardiac disease. Presence of contraindications for the use of laryngeal mask (anatomical abnormalities) increased risk for intubation (mallampati score 4), or compromised upper airway due to extension of primary head and neck cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sensitivity
Time frame: one year
Investigate sensitivity of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to AFB (the 'gold standard') and standard WLB for detecting abnormalities of the tracheobronchial tree. So we used 5 types of bronchoscopy; SWL (=standard white light), HD (=high defenition bronchoscopy without surface/tone enhancement), HD-i-Scan1 (=high defention bronchoscopy with surface enhancement), HD-i-scan 2 (=high defenition bronchoscopy with tone enhancement), AFB (=autofluorescence bronchoscopy). Furthermore we aim to investigate determination of resection margins of (suspected) malignancies in the glottic and supraglottic area or centrally located lung cancer in comparison to autofluorescence bronchoscopy (SAFE 3000 dual video mode) in a high risk population with biopsies from all suspect lesions identified by either technique.
1 secondary outcome
Sensitivity and Specificity of HD Videobronchoscopy
Time frame: one year
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
HFM vanderHeijden, MD principal investigator
Principal Investigator
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Radboud University Medical Center at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 May 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 May 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2015.